List view / Grid view
A study by NYU Langone Medical Centre researchers adds to growing evidence that multiple courses of commonly used antibiotics may have a significant impact on children's development.
24 June 2015 | By Victoria White
Researchers have pinpointed a critical differentiator that separates the effects of bactericidal and bacteriostatic antibiotics: cellular respiration...
18 June 2015 | By Victoria White
A new study shows that the antibiotic azithromycin, often prescribed to cure common infections, kills many multidrug-resistant bacteria very effectively...
28 May 2015 | By Victoria White
Seres Therapeutics has enrolled and dosed the first patient in its Phase 2 clinical study of SER-109 in recurrent CDI in adults...
14 May 2015 | By Victoria White
Jim O’Neill’s Review on Antimicrobial Resistance sets out proposals to overhaul the global antibiotics pipeline over the next ten years...
27 April 2015 | By Victoria White
Three posters on the Extended Spectrum Pleuromutilins (ESP) Programme and one poster on lefamulin were presented at ECCMID 2015...
7 April 2015 | By Victoria White
Patients with pneumonia can initially be treated with most common antibiotics, according to research carried out by University Medical Centre Utrecht...
27 March 2015 | By Victoria White
While antibiotics boast a vast pipeline, the majority is dominated by generics, as weak financial incentives and high fail rates have discouraged innovation..
20 March 2015 | By Victoria White
Scientists should reduce antibiotic use in lab experiments - according to a researcher from UEA’s Norwich Medical School...
30 January 2015 | By Nabriva Therapeutics AG
Nabriva Therapeutics AG announced the appointment of Charles Rowland to the Nabriva Supervisory Board...
18 November 2014 | By Public Health England
Four in ten people take antibiotics for a cough or runny nose despite both conditions normally clearing up without treatment, according to new research out by Public Health England (PHE) for European Antibiotic Awareness Day (EAAD)...
3 November 2014 | By Auspherix Pty Ltd
Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further with AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies...
3 July 2014 | By Department of Health
The Prime Minister David Cameron called for global action to tackle the growing threat of resistance to antibiotics...
